NCT02557126已完成2 期
A Placebo-controlled, Randomized, Double-blind, Multicenter Phase 2 Study to Assess the Efficacy and Safety of URC102 in Gout Patients
JW Pharmaceutical1 个研究点 分布在 1 个国家目标入组 76 人开始时间: 2015年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 76
- 试验地点
- 1
- 主要终点
- Trend of serum uric acid reduction rate (%)
研究概览
简要总结
The purpose of this study is to assess safety, Pharmacokinetics/Pharmacodynamics and Urate Lowering Effect of URC102 in gout patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 69 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Diagnosed with gout
排除标准
- •Participated in other clinical study within 12 weeks prior to enrollment, and received an investigational product (including placebo)
研究组 & 干预措施
URC102
Experimental
URC102
干预措施: URC102 (Drug)
Placebo
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Trend of serum uric acid reduction rate (%)
时间窗: 2 weeks
Trend of serum uric acid levels (mg/dL)
时间窗: 2 weeks
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
3 期
A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)Still's Disease, Adult-OnsetStill's Disease, Juvenile-OnsetNCT03265132Swedish Orphan Biovitrum13
已完成
1 期
Safety, Pharmacokinetics and Pharmacodynamics of DSP-8658 in Patients With Type 2 Diabetes Mellitus and Healthy AdultsType 2 Diabetes MellitusNCT01042106Sumitomo Pharma America, Inc.40
已完成
1 期
A Phase 1b Study of Thymosin Beta 4 in Healthy VolunteersHealthyNCT04555850Beijing Northland Biotech. Co., Ltd.30
已完成
2 期
A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With DermatomyositisDermatomyositisNCT05695950Lakefront Biotherapeutics NV40
终止
4 期
A Study to Evaluate the Use of Extended Release Alprazolam in the Treatment of Adolescents With Panic DisorderPanic DisorderNCT00635531Pfizer's Upjohn has merged with Mylan to form Viatris Inc.16